8 results
8-K
EX-99.1
CADL
Candel Therapeutics Inc
19 May 23
Regulation FD Disclosure
9:15am
B NCT03152318 Arm C
Patient demographics and baseline characteristics 41 unique patients were dosed; one patient was treated twice, in cohort IX
8-K
EX-99.1
CADL
Candel Therapeutics Inc
6 Dec 22
Regulation FD Disclosure
8:01am
demographics and characteristics 52 patients who received at least 1 dose of CAN-2409 comprise the safety population Age Years Baseline ECOG n (%) 0 or 1 21 (40 … methylated and ~24 unmethylated evaluable patients 58
Patient demographics safety population (41 patients) Characteristic N (%) Characteristic N (%) KPS
8-K
EX-99.1
CADL
Candel Therapeutics Inc
6 Jun 22
Regulation FD Disclosure
8:37am
Demographics 35 patients enrolled between October 2020 and April 2022 Data cutoff was April 20, 2022 23
Most frequent treatment-related adverse events
10-K
2021 FY
CADL
Candel Therapeutics Inc
29 Mar 22
Annual report
8:46am
to the demographics of the investigational cohort. For example, 74% of patients in the Toca 511 cohort had a Karnofsky performance score greater than 90, whereas only
424B4
CADL
Candel Therapeutics Inc
28 Jul 21
Prospectus supplement with pricing info
4:02pm
that was poorly matched to the demographics of the investigational cohort. For example, 74% of patients in the Toca 511 cohort had a Karnofsky
S-1/A
mhhse3 02n
16 Jul 21
IPO registration (amended)
6:07am
S-1
cbmc4rb
25 Jun 21
IPO registration
5:28pm
- Prev
- 1
- Next